Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalPremera Bluecross Stem Cell Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy N/A

    Mesenchymal Stem Cell Therapy, Allografts, and Bone Substitutes for Orthopedic Applications

    Customize your policy alerts

    Sign up for all Premera Bluecross policy alerts

    Know when Premera Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy addresses coverage for mesenchymal stem cell therapies and certain allograft or synthetic bone graft products used in orthopedic applications.

    Policy Summary
    PayerPremera Bluecross
    PolicyMesenchymal Stem Cell Therapy, Allografts, and Bone Substitutes for Orthopedic Applications
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOctober 1, 2026
    Last ReviewMar 23, 2026
    Next Review DateN/A
    Key ActionTreat orthopedic mesenchymal stem cell therapies and specified stem cell-containing graft products as investigational.
    SourceLink
    POLICY UPDATE CHANGES

    In 2013, allograft bone containing viable stem cells was designated investigational.

    In 2015, bone graft substitutes requiring autologous blood or bone marrow aspirate were designated investigational.

    An out-of-network-facility statement was removed.

    CPT code 1095T was added.

    CPT codes 0263T, 0264T, 0265T, and 38241 were removed.

    In 2024, the policy clarified its scope for bone matrix products not involving stem cell use.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    AllOrthopedic applications considered investigational
    5 CPTCodes inappropriate for orthopedic stem cell therapy billing
    1New CPT code added
    4CPT codes removed
    ExcludedMedicare Advantage applicability

    Coverage Criteria

    Mesenchymal Stem Cell Therapy

    The following services are considered investigational for all orthopedic applications:

    Mesenchymal stem cell therapy, including use in repair or regeneration of musculoskeletal tissue.

    Allograft Bone Products Containing Viable Stem Cells

    The following products are considered investigational for all orthopedic applications:

    Allograft bone products containing viable stem cells, including, but not limited to, demineralized bone matrix (DBM) with stem cells.

    Allograft or Synthetic Bone Graft Substitutes Requiring Autologous Blood or Bone Marrow

    The following products are considered investigational for all orthopedic applications:

    Allograft or synthetic bone graft substitutes that must be combined with autologous blood or bone marrow.

    Osteoarthritis Guideline Positions

    Clinical practice guidelines recommend against stem cell injections for osteoarthritis in specified circumstances:

    ALL of the following guideline positions apply

    • The 2019 American College of Rheumatology and Arthritis Foundation guidelines gave a strong recommendation against stem cell injections for patients with knee and/or hip osteoarthritis, citing heterogeneity in preparations and lack of standardization of techniques.
    • The same 2019 guidelines made no recommendation for hand osteoarthritis because the efficacy of stem cells has not been evaluated.
    • The 2020 Department of Veterans Affairs/Department of Defense clinical practice guideline gave a weak-against recommendation for stem cell injections, including mesenchymal, adipose-derived, and bone marrow-derived stem cells, for treatment of knee osteoarthritis.

    FDA HCT/P Regulatory Pathway

    An HCT/P is regulated solely under section 361 of the Public Health Service Act and 21 CFR Part 1271 only when ALL of the following criteria are met. If an HCT/P does not meet these criteria and does not qualify for a stated exception, it is regulated as a drug, device, and/or biological product, and applicable regulations and premarket review are required.

    ALL of the following

    • The HCT/P is minimally manipulated.
    • The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.
    • The manufacture of the HCT/P does not involve combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition does not raise new clinical safety concerns with respect to the HCT/P.
    • ONE of the following

      • The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function.

    This policy does not address unprocessed allograft bone or products that do not require mixing with stem cells. See Table 2 under Regulatory Status for product examples for informational purposes.

    The FDA does not consider the use of stem cells for orthopedic procedures to be homologous use.

    Concentrated autologous mesenchymal stem cells do not require approval by the FDA. No products using engineered or expanded mesenchymal stem cells have been approved by the FDA for orthopedic applications.

    This policy does not apply to Medicare Advantage.

    Coding and Reporting

    CPT codes not appropriate for orthopedic stem cell therapiesCPTNot Covered
    38205Not appropriate when billed for stem cell therapies for orthopedic applications.
    38206Not appropriate when billed for stem cell therapies for orthopedic applications.
    38230Not appropriate when billed for stem cell therapies for orthopedic applications.
    38232Not appropriate when billed for stem cell therapies for orthopedic applications.
    38241Not appropriate when billed for stem cell therapies for orthopedic applications.
    CPT codes for reporting orthopedic stem cell proceduresCPT
    0565TAutologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation.
    0566TAutologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral.
    0717TAutologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs.
    0718TAutologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral.
    1095THarvesting and processing of autologous bone marrow aspirate concentrate (BMAC), with application onto scaffold or injection into anatomical recipient site (e.g., subchondral bone, joint space, chondral lesion), including imaging guidance, when performed, for therapeutic musculoskeletal treatment, excluding spinal procedures (new code effective 10/01/26).
    20999Unlisted procedure, musculoskeletal system, general (when used to describe harvesting and injection of bone marrow aspirate concentrate or harvesting and
    FDA Product Codemixed
    MQVFDA product code for certain demineralized bone matrix combination products cleared through the 510(k) process.
    Representative FDA 510(k) Clearance Numbersmixed
    K083033Vitoss Bioactive Foam Bone Graft Substitute
    K081558NanOss BVF-E
    K070751OrthoBlast II Demineralized Bone Matrix putty and paste
    K053218DBX Demineralized bone matrix putty, paste and mix
    K050789Formagraft Collagen Bone Graft Matrix
    K040419DynaGraft II Gel and Putty
    K071237CopiOs Bone Void Filler
    K062353Integra MOZAIK Osteoconductive Scaffold-Putty
    Added CPT CodeCPT
    1095THarvesting and processing of autologous bone marrow aspirate concentrate (BMAC), with application onto scaffold or injection into anatomical recipient site (e.g., subchondral bone, joint space, chondral lesion), including imaging guidance, when performed, for therapeutic musculoskeletal treatment, excluding spinal procedures.
    Removed CPT CodesCPTNot Covered
    0263TDescription not provided in this window
    0264TDescription not provided in this window
    0265TDescription not provided in this window
    38241Description not provided in this window
    Historically Added CPT CodeCPT
    20999Description not provided in this window
    Historically Removed CPT CodeCPTNot Covered
    38230Description not provided in this window
    Historical CPT Coding UpdatesCPT
    0565TDescription not provided in this window
    0566TDescription not provided in this window
    38206Description not provided in this window

    Provider and Billing Actions

    Denial Risk

    Investigational Orthopedic Stem Cell or Graft Therapy

    Treat mesenchymal stem cell therapy and allograft or synthetic bone graft products containing viable stem cells or requiring combination with autologous blood or bone marrow as investigational for all orthopedic applications, including musculoskeletal tissue repair or regeneration.

    • Mesenchymal stem cell therapy is investigational for all orthopedic applications.
    • Allograft bone products containing viable stem cells, including demineralized bone matrix (DBM) with stem cells, are investigational for all orthopedic applications.
    • Allograft or synthetic bone graft substitutes that must be combined with autologous blood or bone marrow are investigational for all orthopedic applications.
    • This policy does not address unprocessed allograft bone or products that do not require mixing with stem cells; see Table 2 under Regulatory Status for product examples.

    Clinical Background

    Mesenchymal stem cells (MSCs) are multipotent adult cells that may differentiate into musculoskeletal tissues, including bone, cartilage, tendon, ligament, muscle, and fat. Orthopedic applications under study include repair or regeneration of damaged bone, cartilage, ligaments, tendons, intervertebral discs, joint defects, and osteonecrosis. Evidence remains low quality or insufficient to establish improved net health outcomes, with continued uncertainty regarding cell source, harvesting, preparation, delivery method, and long-term safety.

    Definitions

    Mesenchymal stem cells (MSCs)
    DefinitionMultipotent cells that can differentiate into various tissues, including trabecular bone, tendon, articular cartilage, ligaments, muscle, and fat.
    Alternate terminologyAlso called multipotent stromal cells.
    Musculoskeletal relevanceMSCs are associated with blood vessels within bone marrow, synovium, fat, and muscle, where they may be mobilized for endogenous repair.
    Cell therapy
    DefinitionThe application of mesenchymal stem cells directly to a musculoskeletal site.
    Cell sourceThe cells used are mesenchymal stem cells, also called multipotent stromal cells.
    Policy Summary
    PayerPremera Bluecross
    PolicyMesenchymal Stem Cell Therapy, Allografts, and Bone Substitutes for Orthopedic Applications
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOctober 1, 2026
    Last ReviewMar 23, 2026
    Next Review DateN/A
    Key ActionTreat orthopedic mesenchymal stem cell therapies and specified stem cell-containing graft products as investigational.
    SourceLink
    On This Page
    Coverage CriteriaCoding and ReportingProvider and Billing ActionsClinical BackgroundDefinitions
  1. ALL of the following

    • The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function.
    • ONE of the following permitted uses

      • The HCT/P is for autologous use.
      • The HCT/P is for allogeneic use in a first-degree or second-degree blood relative.
      • The HCT/P is for reproductive use.
  2. Billing Rule

    Do Not Bill Transplantation-Service Codes

    Do not report transplantation-service CPT codes for orthopedic stem cell therapies because transplantation services are not being performed. When no specific CPT or HCPCS code is available, report the appropriate unlisted procedure code for the body area in which the procedure is performed.

    • Do not use CPT 38205, 38206, 38230, 38232, or 38241 for orthopedic stem cell therapies.
    • The listed unlisted codes may not be all-inclusive; select the appropriate unlisted procedure code for the body area treated when no specific CPT or HCPCS code is available.
    Denial Risk

    Verify HCT/P Criteria and Homologous Use

    Before billing or requesting coverage, confirm that the human cells, tissues, or cellular and tissue-based product (HCT/P) satisfies all section 361 of the Public Health Service Act and 21 CFR Part 1271 criteria. Products that do not meet the criteria or an applicable exception are regulated as drugs, devices, and/or biological products and require applicable regulation and premarket review; orthopedic stem cell use is not considered homologous use by the FDA.

    • The HCT/P must be minimally manipulated.
    • The HCT/P must be intended for homologous use only, as reflected by labeling, advertising, or the manufacturer's objective intent. The FDA does not consider use of stem cells for orthopedic procedures to be homologous use.
    • Manufacture must not combine the cells or tissues with another article, except water, crystalloids, or a sterilizing, preserving, or storage agent, unless the addition raises new clinical safety concerns.
    • The HCT/P must either have no systemic effect and not depend on the metabolic activity of living cells for its primary function, or, if it does have a systemic effect or depend on living-cell metabolic activity, be intended for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.
    • If the HCT/P fails these criteria and does not qualify for a stated exception, anticipate denial risk and applicable drug, device, and/or biological-product requirements.
    Application site
    The treatment is applied directly to a site within the musculoskeletal system.
    Tissue engineering
    DefinitionTechniques that use mesenchymal stem cells and/or bioactive molecules, such as growth factors, in combination with scaffolds.
    PurposeThe techniques are intended to improve the efficiency of repair or regeneration.
    Tissue focusThe repair or regeneration addressed is for damaged musculoskeletal tissues.
    Bone-marrow aspirate
    DefinitionThe most accessible and most common source for isolating mesenchymal stem cells for treatment of musculoskeletal disease.
    Harvesting considerationHarvesting mesenchymal stem cells from bone marrow requires a procedure that may result in donor-site morbidity.
    Cell limitationsThe number of mesenchymal stem cells in bone marrow is low, and their number and differentiation capacity decrease with age.
    Human cells, tissues, and cellular and tissue-based product (HCT/P)
    DefinitionHuman cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient.
    Regulatory scopeHCT/Ps are regulated by the US Food and Drug Administration through the Center for Biologics Evaluation and Research under 21 CFR parts 1270 and 1271.
    When additional regulation may applyIf an HCT/P does not meet the applicable criteria or stated exceptions, it may be regulated as a drug, device, and/or biological product, with applicable regulations and premarket review required.
    Homologous use
    DefinitionAn HCT/P use reflected by product labeling, advertising, or other indications of the manufacturer's objective intent.
    Recipient-donor functionFor homologous use, the cells or tissues perform the same basic function in the recipient as in the donor.
    Orthopedic applicationThe FDA does not consider the use of stem cells for orthopedic procedures to be homologous use.
    Minimal manipulation
    DefinitionMinimal manipulation is an HCT/P processing condition required for regulation solely under section 361 of the Public Health Service Act and 21 CFR Part 1271.
    Section 361 pathwayAn HCT/P must be minimally manipulated to qualify for regulation solely under section 361 and 21 CFR Part 1271.
    Related conditionThe HCT/P must also be intended for homologous use only, as reflected by labeling, advertising, or other indications of the manufacturer's objective intent.
    MSCs
    AbbreviationMSCs.
    Expanded termMesenchymal stem cells.
    Cell typeMSCs are multipotent cells that can differentiate into various tissues, including trabecular bone, tendon, articular cartilage, ligaments, muscle, and fat.